Here's a story about ambition, debt, and the kind of bet that makes everyone in the room sit up a little straighter. Mumbai-based Sun Pharmaceutical Industries, led by Dilip Shanghvi, is getting ready to write a very big check. We're talking about a binding $12 billion offer for Organon & Co. (OGN), the U.S. women's health-focused drugmaker. If this goes through, it won't just be another acquisition—it'll be the largest overseas purchase ever made by an Indian pharmaceutical company. That's the kind of move that gets you a chapter in the business school textbooks.

From Due Diligence to Deal Time

According to people familiar with the matter, Sun Pharma has just wrapped up an extensive due diligence process that lasted more than three months. Think of it as the corporate equivalent of kicking the tires, checking under the hood, and getting a full mechanical inspection on a used car, except the car costs twelve billion dollars and comes with a portfolio of pharmaceuticals.

Now, the company is in the final stretch: sorting out the financing. They've reportedly brought in at least three global banks to help back the transaction. This isn't just window shopping anymore. When you start mandating banks, you're signaling you're serious about getting to the finish line. A firm bid is expected in the coming weeks.

Why Organon? And Why Now?

This potential mega-deal didn't come out of nowhere. Sun Pharma has had its eye on Organon for a while. You might remember Organon as the company spun off from pharma giant Merck & Co Inc. (MRK) back in 2021. Earlier this year, in January, Sun Pharma submitted a non-binding offer and then got to work on that deep dive due diligence we just talked about. They've also been in talks with major financial institutions to line up the funding.

So, what's the appeal? For Sun Pharma, it's a strategic shift. The company has indicated it wants to evolve from its roots into a more innovation-driven, branded pharmaceutical player. Buying Organon, with its focus on women's health and biosimilars, would be a giant leap in that direction.

For Organon, the timing might be right because, frankly, it's been a tough run. The company has faced pressure across its key business segments—women's health, biosimilars, and established medicines. It's also been carrying a hefty debt load it inherited from the spinoff, though it did manage to whittle that down to $8 billion in 2025 from $9.5 billion. The market hasn't been kind either; Organon's shares are down over 19% year-to-date, despite a brief rally when news of Sun Pharma's interest first surfaced.

The company has been trying to reshape itself, selling off assets like its JADA post-partum hemorrhage treatment system to focus on strengthening its core biopharma business. Sometimes, when you're streamlining and the stock is down, you become a very attractive target for someone with a big checkbook and a plan.

The Financial Muscle Behind the Move

The big question is always: can they afford it? In Sun Pharma's case, the answer looks like a solid maybe. The company is sitting on approximately $3.2 billion in net cash. That's a serious war chest. They've also said publicly that they're willing to deploy capital for large-scale acquisitions. When you combine the cash with the willingness, you get the kind of environment where a $12 billion deal starts to look plausible, not just pie-in-the-sky.

And the market is certainly paying attention. At the time of publication, Organon shares were up a staggering 27.93% at $8.01. That's what happens when a potential white knight with deep pockets comes riding into town.

So, we're left watching the final preparations. Due diligence: done. Financing: being finalized. The bid: imminent. If Sun Pharma pulls this off, it won't just be buying a company; it'll be making a statement about the global ambitions of Indian pharma. And for Organon, it could be the strategic reset it's been looking for. It's a high-stakes game, and the next few weeks will tell us if they're ready to go all in.